The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Takecab Tops in GP and HP Markets for 3rd Month in a Row in March: Anterio Ranking
May 8, 2015
- Oncolys Initiates PI Trial of Novel Anticancer Drug in Patients with Solid Cancers in the US
May 8, 2015
- US Drug Spending Spikes in 2014 Lifted by Cancer, Hepatitis C Medicines: IMS
May 7, 2015
- PhRMA Member Companies Invest US$51.2 Billion in New Drug R&D in 2014
May 7, 2015
- US Sales of Abilify Rise 2.4% in January-March: Otsuka Holdings
May 7, 2015
- Zeria Cuts FY2014 Forecasts, to Lose 40% of Estimated Profits
May 7, 2015
- Fujifilm Holdings Acquires Cellular Dynamics International through Tender Offer
May 7, 2015
- Nichi-Iko Most Favored Maker of Plavix Generics: Survey
May 1, 2015
- Takeda Agrees to Pay US$2.37 Billion to Settle Actos Suits, Braces for 1st Net Loss
May 1, 2015
- Toho Holdings Names Hiroyuki Kono as Next Chairman
April 30, 2015
- Daiichi Sankyo Cuts FY2014 Forecasts on Write-Off Loss Tied to Zelboraf
April 30, 2015
- Boehringer Japan Pharma Sales Grow 3 Times Faster than Market in 2014
April 30, 2015
- Eliquis Shows Lower Incidence of Adverse Events Including Major Bleeding in PIII Study in Patients with Acute VTE
April 28, 2015
- Lixiana Recommended for European Approval by CHMP: Daiichi Sankyo
April 28, 2015
- Sanofi Files Primaquine for Vivax Malaria, Ovale Malaria in Japan
April 28, 2015
- Novartis Seeks Japan Approval for 2 Malignant Melanoma Drugs Transferred from GSK
April 28, 2015
- Eisai, Nihon Medi-Physics Tie Up for Diagnosis, Treatment of Dementia with Lewy Bodies
April 28, 2015
- Opdivo Gains Positive CHMP Opinion for Advanced Melanoma
April 27, 2015
- Takeda’s Shonan Lab Collaborative Research Initiative Forging Ahead
April 27, 2015
- Janssen Files Risperdal for Irritability Associated with Autistic Disorder in Children
April 27, 2015
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…